R

Roche

Global pharmaceuticals and diagnostics company

Head of Import and Export

Full-TimeUpdated on 10/22/2026
No salary listed
Expert
Bachelor's
Shanghai, China
In Person
Operations & LogisticsLogistics & Transportation

About the job

Requirements
  • A bachelor's degree or above is required; a background in international trade, logistics, or supply chain is preferred.
  • At least 10 years of experience in import/export management, with in-depth knowledge of Chinese Customs regulations, policies, and enterprise auditing processes.
  • Proficiency in medical device importation.
  • Fluent English communication skills for collaboration with team members and stakeholders.
  • Strong cross-functional collaboration and execution skills, including the ability to drive project progress and resolve complex issues.
  • A detail-oriented and rigorous work style.
  • Ability to think strategically and translate strategies into actionable plans.
  • Previous experience importing biotechnology products, including DS/DP, and experience in multinational companies are highly desirable.
  • Ability to exercise leadership and influence with or without direct line authority.
  • A strong sense of accountability and ownership, and resilience under pressure.
Responsibilities
  • Build and implement end-to-end import and export strategies and operating models suited to different business strategies, product types, and imported materials.
  • Ensure seamless execution of import and export activities, including customs declarations, goods clearance, and logistics coordination.
  • Act as the local Export Control and Sanctions Officer, implementing or improving the company's local export-control and sanctions compliance program and ensuring local compliance.
  • Collaborate with project teams, global functions, and local departments to establish and optimize import/export management systems, policies, and procedures in compliance with company requirements and Chinese laws and regulations.
  • Ensure import/export requirements, including product, raw-material, and equipment imports and related documentation, are addressed in project planning.
  • Build and maintain relationships with customs authorities, inspection authorities, logistics providers, and third-party agencies to secure permits and project resources.
  • Provide guidance and training to new team members on import/export processes and responsibilities.
  • Supervise and guide import/export activities to ensure compliance with Chinese laws and regulations and global company requirements.
  • Organize and lead cross-functional teams to establish and maintain import/export processes, including business licenses, customs audits, and certifications.
  • Work with CA, FA, and Legal on investigations or audits by customs, the Commission of Economy and Information Technology, Tax Bureaus, and other authorities.
  • Interpret customs laws and regulations, monitor changes, and shape company policies to support compliant operations.
  • Review, update, and maintain policies and process documents in line with changing Chinese regulations and global trade practices.
  • Maintain relationships with local authorities, including Shanghai Customs, Pudong Customs, Airport Customs, CIQ, NMPA, and SCC, to facilitate operations and obtain import licenses.
  • Manage suppliers and logistics service providers to ensure service quality and efficiency, and resolve operational crises in a timely manner.
  • Monitor policy changes and global trade trends to refine and optimize import/export strategies.
  • Implement or improve the local EC&S IMCP Export program, with particular focus on training employees to seek guidance when unsure about proper business conduct.
  • Keep the General or Site Manager informed about export-control and sanctions compliance issues, and maintain related local standard operating procedures.
  • Define the local EC&S training plan, deliver training, and monitor its completion.
  • Ensure manual screening procedures and tools are used and local business partners, including customers and vendors, are screened completely and on time.
  • Oversee use of export-control contractual clauses in procurement and sales, with particular attention to foreign-trade business.
  • Escalate export-control issues to the Chief Export Control Compliance Officer in cases involving red flags, suspected misuse of items, non-compliance violations, or local enforcement activity.
  • Maintain local export-control standard operating procedures; classify local items or delegate classification; review or release documents blocked by SAP GTS if used; apply for export-control licenses or delegate applications; and ensure license conditions are followed.
  • Take responsibility for export-control product-classification expertise.
Desired Qualifications
  • Previous experience importing biotechnology products, including DS/DP, and experience in multinational companies are highly desirable.
  • A background in international trade, logistics, or supply chain is preferred.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.

PR Newswire
Sep 30th, 2026
Roche launches newborn screening test for SMA, SCID and sickle cell disease

Roche has launched a newborn screening test that simultaneously detects three severe genetic conditions: Spinal Muscular Atrophy, Severe Combined Immunodeficiency Disease, and Sickle Cell Disease. TIB MOLBIOL, a Roche subsidiary, developed the LightMix Newborn TREC/SMN1/HBB kit for use in countries accepting the CE mark. The test enables early detection before symptoms appear, allowing clinicians to initiate life-changing treatments sooner. Early intervention can prevent severe nerve damage in SMA, enable lifesaving bone marrow transplants for SCID, and drastically lower infant mortality in SCD through preventive measures. The IVDR-approved test provides a ready-to-use solution that integrates into existing laboratory workflows. It runs on established LightCycler systems, making it accessible for private and academic hospital laboratories across Europe.

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.